Somewhat Favorable News Coverage Somewhat Unlikely to Impact Xenetic Biosciences (XBIO) Share Price

Media headlines about Xenetic Biosciences (NASDAQ:XBIO) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Xenetic Biosciences earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.8936700639503 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of Xenetic Biosciences (NASDAQ XBIO) opened at $2.10 on Wednesday. Xenetic Biosciences has a twelve month low of $1.75 and a twelve month high of $5.90.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings data on Monday, August 14th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.13). analysts forecast that Xenetic Biosciences will post -0.89 EPS for the current fiscal year.

Separately, Zacks Investment Research lowered Xenetic Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, September 13th.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Xenetic Biosciences (XBIO) Share Price” was first published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.

Insider Buying and Selling by Quarter for Xenetic Biosciences (NASDAQ:XBIO)

Receive News & Ratings for Xenetic Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences Inc. and related companies with's FREE daily email newsletter.

Leave a Reply